Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.
about
Therapeutic potential of PDE modulation in treating heart diseaseMeasurement of Reactive Oxygen Species, Reactive Nitrogen Species, and Redox-Dependent Signaling in the Cardiovascular System: A Scientific Statement From the American Heart Association.Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failureAdvances in targeting cyclic nucleotide phosphodiesterasesParkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain.Claudin-5 levels are reduced from multiple cell types in human failing hearts and are associated with mislocalization of ephrin-B1.Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling networkTadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.Exercise training in adverse cardiac remodeling.Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation.Novel Sulfur Metabolites of Garlic Attenuate Cardiac Hypertrophy and Remodeling through Induction of Na+/K+-ATPase Expression.The role of B-type natriuretic Peptide testing in guiding outpatient heart failure treatment.Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation.
P2860
Q27005761-44F3C503-63B3-4F68-8C92-4E541E132E1DQ30248995-C2EC9144-A566-48A1-A518-5372D04BF470Q33783174-9A7F1DD2-94FA-4A23-BFC4-B14F2CBB7FD7Q34139490-44B010C3-C621-4032-A599-AC922D82E357Q34806899-124963AB-2AEA-4579-B872-16219617E9A8Q35582658-765014D4-27B1-44D9-98B5-C63AC65B646AQ36609843-61D286D9-2EC3-48BB-A497-987D871E78C3Q37240478-F829B879-D2CA-425B-902C-F3A720405240Q38191440-D84440C2-0AFD-49BE-B6E6-0B3FE284617BQ38862807-0B4B26E7-4CD7-4E8A-91EB-4A038F488F59Q38963183-54DE61D8-ED50-46AB-B6CD-A876895FF0B7Q43513997-897504D2-7EA8-4088-858A-036A0521D8BBQ54121051-FF2A1C1D-83FC-4F17-A421-6B332402D70D
P2860
Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pathological cardiac hypertrop ...... natriuretic peptide signaling.
@ast
Pathological cardiac hypertrop ...... natriuretic peptide signaling.
@en
type
label
Pathological cardiac hypertrop ...... natriuretic peptide signaling.
@ast
Pathological cardiac hypertrop ...... natriuretic peptide signaling.
@en
prefLabel
Pathological cardiac hypertrop ...... natriuretic peptide signaling.
@ast
Pathological cardiac hypertrop ...... natriuretic peptide signaling.
@en
P2093
P2860
P1433
P1476
Pathological cardiac hypertrop ...... natriuretic peptide signaling.
@en
P2093
Aiyang Jiang
Ajay M Shah
Celio X C Santos
David A Kass
Djahida Bedja
Dong-ik Lee
Eiki Takimoto
Manling Zhang
Philip Eaton
Steven Hsu
P2860
P304
P356
10.1161/CIRCULATIONAHA.112.090977
P407
P577
2012-07-24T00:00:00Z